Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medicinova (MNOV) Capital Expenditures (2021 - 2025)

Medicinova (MNOV) has disclosed Capital Expenditures for 6 consecutive years, with $2002.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures changed N/A to $2002.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $4730.0, a N/A change, with the full-year FY2025 number at $2899.0, up 223.91% from a year prior.
  • Capital Expenditures was $2002.0 for Q4 2025 at Medicinova, up from $6.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $22271.0 in Q2 2021 to a low of -$22.0 in Q4 2023.
  • A 4-year average of $4989.8 and a median of $2373.0 in 2023 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 99.78% in 2024; the steepest drop was 99.78% in 2024.
  • Medicinova's Capital Expenditures stood at $2938.0 in 2021, then plummeted by 100.75% to -$22.0 in 2023, then surged by 127.27% to $6.0 in 2024, then surged by 33266.67% to $2002.0 in 2025.
  • Per Business Quant, the three most recent readings for MNOV's Capital Expenditures are $2002.0 (Q4 2025), $6.0 (Q3 2024), and -$22.0 (Q4 2023).